Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.88 | N/A | -14.49% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.88 | N/A | -14.49% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current performance but highlighted initiatives aimed at enhancing productivity. They did not provide specific guidance for future quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.
Future prospects were discussed, but no specific guidance was provided.
PTC Therapeutics reported a larger-than-expected loss per share, which contributed to a cautious tone from management. Despite the miss on EPS, the stock reacted positively, rising by 0.77%. Investors may be encouraged by management's focus on improving operations, even in the absence of specific guidance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERIPRISE FINL INC
Apr 24, 2023